GlassScriptPhysician profile
Edward Charles Federman
NPI 1548369648
$8,564.65
in general payments reported to CMS, 2019-2025
43 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,098 · 2020: $443 · 2021: $1,556 · 2022: $1,086 · 2023: $1,101 · 2024: $1,157 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,280 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,280.25 |
| Education | $101.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,956.47 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Uk Limited | $1,490.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,020.01 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Medtronic, INC. | $900.00 | 2021 | |
| Insmed, INC. | $420.40 | 2020-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.59 | 2019-2024 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Pfizer INC. | $280.88 | 2019-2025 | |
| Grifols USA, LLC | $262.65 | 2023-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $179.87 | 2019-2024 | Uptravi, Opsumit |
| Genzyme Corporation | $171.43 | 2021-2025 | |
| Astellas Pharma US INC | $164.63 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $129.79 | 2020-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $128.28 | 2019-2021 | |
| Mylan Specialty L.P. | $123.12 | 2021-2024 | Yupelri |
| Gilead Sciences, INC. | $113.06 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 | |
| Electromed, INC. | $70.99 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $70.59 | 2021-2024 | Nuzyra |
| Sanofi Pasteur INC. | $63.73 | 2019-2025 | |
| Genentech USA, INC. | $60.06 | 2021 | |
| Amgen INC. | $53.16 | 2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $53.12 | 2019 | |
| Melinta Therapeutics, LLC | $41.31 | 2023 | Vabomere, Orbactiv, Kimyrsa |
| Philips North America LLC | $36.83 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $31.29 | 2025 | Purified Cortrophin Gel |
| 3b Medical, INC. | $29.57 | 2023 | Luna |
| Verona Pharma, INC. | $26.74 | 2025 | Ohtuvayre |
| Baxter Healthcare | $25.91 | 2023 | Hillrom - Life 2000 Ventilation System |
| Shionogi INC | $25.17 | 2024 | Fetroja |
| Octapharma USA, INC. | $23.98 | 2024 | Octagam Immune Globulin (Human) |
| Seqirus USA INC | $23.74 | 2024 | Flucelvax, Fluad |
| Harmony Biosciences LLC | $23.38 | 2022 | |
| Boston Scientific Corporation | $23.17 | 2021 | |
| Phadia US INC. | $18.02 | 2024 | Immunocap |
| Jazz Pharmaceuticals INC. | $16.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.93 | 2021 | |
| Resmed Corp | $14.46 | 2019 | |
| Electronic Waveform Lab, INC. | $11.76 | 2024 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Federman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.